Skip to main content
. 2020 Feb 20;10:3080. doi: 10.1038/s41598-020-58366-z

Figure 2.

Figure 2

Kaplan-Meier plots of the rates of progression-free survival (PFS; 2A) and overall survival (OS; 2B) of patients with metastatic TP53 mutant solid tumors treated with pazopanib and vorinostat (n = 11) or ixazomib and vorinostat (n = 59).